Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsActivities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in miceEfficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans DiseaseLack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic ReviewInfections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation.Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review.Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomesProbable Buruli Ulcer Disease in Honduras.Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease.Management of BU-HIV co-infection.Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer
P2860
Q24631021-5ACBC709-61D2-4C53-ABA1-2CD5FE631A4DQ28476689-C2847CDF-F2FA-42E2-8C2A-AA95FDC1D424Q28552524-DADBDA18-658F-41F7-90FA-A7832319DD2AQ33658786-80C7E47E-52CA-404D-AB2A-F57648955D93Q34481015-8EB9481F-2540-4FB2-9896-1F7BB8BF7882Q35084312-355A56C2-7FCF-46EB-8144-8485B742DDBBQ36507843-8B1A6B82-7D94-490C-8CBD-852EA7B70623Q36900084-B096C957-8879-4016-924F-ABABEF050C9AQ37544684-BFEE61A3-24B6-4733-8B30-78BB0B92205CQ37713494-A417FFFF-F0A6-47A9-8615-47A7B7F105C2Q38221645-746DD1E6-FBEA-4F9D-8A6D-ADB5C2EEA450Q38838051-A325DFE8-24E3-49BC-AB96-8B58B1CC4673Q39496473-D651842E-3EDB-464E-A9B3-556A34711523Q40095703-C200D730-2A80-4149-904F-AC2A6FEEC625Q40789030-FE23E185-1DDA-430F-ADE8-C5A01824A213Q42717214-CA9E74B1-4969-43FA-9C35-D3322DE914AAQ50668713-4A229FF9-85D9-4970-AB57-2133B7684414Q58785246-9E158EE8-82DD-4C56-AC65-38BA104D3F8E
P2860
Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacokinetics of rifampin a ...... obacterium ulcerans infection.
@ast
Pharmacokinetics of rifampin a ...... obacterium ulcerans infection.
@en
Pharmacokinetics of rifampin a ...... obacterium ulcerans infection.
@nl
type
label
Pharmacokinetics of rifampin a ...... obacterium ulcerans infection.
@ast
Pharmacokinetics of rifampin a ...... obacterium ulcerans infection.
@en
Pharmacokinetics of rifampin a ...... obacterium ulcerans infection.
@nl
prefLabel
Pharmacokinetics of rifampin a ...... obacterium ulcerans infection.
@ast
Pharmacokinetics of rifampin a ...... obacterium ulcerans infection.
@en
Pharmacokinetics of rifampin a ...... obacterium ulcerans infection.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of rifampin a ...... cobacterium ulcerans infection
@en
P2093
A M A Wessels
D R A Uges
F de Velde
J W C Alffenaar
W A Nienhuis
P2860
P304
P356
10.1128/AAC.00099-10
P407
P577
2010-06-28T00:00:00Z